In addition, an Erbitux-based IL-21 tumor-targeting fusion protein (Erb-IL-21) can extend the half-life of IL-21, effectively expand cytotoxic T lymphocytes, and improve its anti-tumor efficacy [37]. The gene discussed is IL21; the disease is neoplasm.